Investor Presentaiton

Neuroscience Anti-MTBR-Tau elF2B Activator elF2B Activator (BMS-986419): Potential across a range of neurodegenerative conditions Misfolded protein accumulation & evidence of ISR activation is present in multiple neurological conditions¹ Frontotemporal Dementia Amyotrophic Lateral Sclerosis Figure adapted from Hetz et al, Nat Rev Neur 2017 Alzheimer's Disease BMS-986419: Safe and well-tolerated in Phase 1 SAD/MAD study potential opportunity as monotherapy or combinations • Stressed cells that develop a chronically activated ISR accumulate misfolded proteins that impair cell functions and can lead to cell death The elF2 complex is an ISR "master regulator" that becomes dysfunctional in chronic disease BMS-986419 binds to a subunit in the eIF2 complex (elF2B) restoring normal ISR function, protein clearance and cellular homeostasis Phase 2 study in ALS initiating in 2024 ALS: Rapidly progressing & fatal neurodegenerative disease caused by death of motor neurons: • • Survival is typically only 2-5 years from symptom onset³ ~39k4 diagnosed prevalent patients in the U.S. Limited treatment options 1. Bristol Myers Squibb ISR: Integrated Stress Response Hetz et al, Nat Rev Neur. 2017. 2. Smith et al, Brain 2016. 3. Masron et al, Eur J Neur 2020. 4. Decision Resources Group, BMS Internal Analysis; Not for Product Promotional Use 130

View entire presentation